TY - JOUR
T1 - Bcl-2 immunohistochemistry in a surgical series of non-small cell lung cancer patients
AU - Fleming, M. V.
AU - Guinee, Jr
AU - Chu, W. S.
AU - Freedman, A. N.
AU - Caporaso, N. E.
AU - Bennett, W. P.
AU - Colby, T. V.
AU - Tazelaar, H.
AU - Abbondanzo, S. L.
AU - Jett, J.
AU - Pairolero, P.
AU - Trastek, V.
AU - Liotta, L. A.
AU - Harris, C. C.
AU - Travis, W. D.
PY - 1998
Y1 - 1998
N2 - The bcl-2 gene is implicated in oncogenesis by its ability to prolong cell survival through the inhibition of apoptosis, without increasing cell proliferation. An association between immunohistochemical staining for bcl-2 protein and the histological type and prognosis of non-small cell carcinoma was hypothesized by Pezzella et al. (N Engl J Med 329:690-694, 1993). In a case series, we stained formalin-fixed, paraffin-bedded tumor tissue from 106 surgical non-small cell lung cancer patients with an antibody to bcl-2 protein (DAKO clone 124, Carpinteria, CA). The resulting bcl-2 staining data were evaluated for associations with demographic, histological, immunohistochemical, and genetic features, including p53 mutations. Bcl-2 staining was observed in tumors from 29 of 106 (27%) of subjects, but was significantly less frequent in subjects' adenocarcinoma histology (8 of 55, 14.6%) (P = .007). This finding persisted after adjustment for age, gender, stage, grade, smoking history, and disease-free survival. In univariate analyses, no association was seen with age, weight, body mass index, gender, or pack-years smoking; tumor grade, stage, or patient performance status; p53 or c-erbB2 immunohistochemical staining, or p53 mutations. These data agree with earlier reports that bcl-2 staining is less common in adenocarcinomas; however, our data do not support the hypothesis that bcl-2 staining confers a better prognosis overall, in squamous cell carcinoma, or in an older patient population.
AB - The bcl-2 gene is implicated in oncogenesis by its ability to prolong cell survival through the inhibition of apoptosis, without increasing cell proliferation. An association between immunohistochemical staining for bcl-2 protein and the histological type and prognosis of non-small cell carcinoma was hypothesized by Pezzella et al. (N Engl J Med 329:690-694, 1993). In a case series, we stained formalin-fixed, paraffin-bedded tumor tissue from 106 surgical non-small cell lung cancer patients with an antibody to bcl-2 protein (DAKO clone 124, Carpinteria, CA). The resulting bcl-2 staining data were evaluated for associations with demographic, histological, immunohistochemical, and genetic features, including p53 mutations. Bcl-2 staining was observed in tumors from 29 of 106 (27%) of subjects, but was significantly less frequent in subjects' adenocarcinoma histology (8 of 55, 14.6%) (P = .007). This finding persisted after adjustment for age, gender, stage, grade, smoking history, and disease-free survival. In univariate analyses, no association was seen with age, weight, body mass index, gender, or pack-years smoking; tumor grade, stage, or patient performance status; p53 or c-erbB2 immunohistochemical staining, or p53 mutations. These data agree with earlier reports that bcl-2 staining is less common in adenocarcinomas; however, our data do not support the hypothesis that bcl-2 staining confers a better prognosis overall, in squamous cell carcinoma, or in an older patient population.
KW - Apoptosis
KW - Bcl-2
KW - Immunohistochemistry
KW - Lung carcinoma
KW - Non-small cell
UR - http://www.scopus.com/inward/record.url?scp=0031964567&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031964567&partnerID=8YFLogxK
U2 - 10.1016/S0046-8177(98)90391-4
DO - 10.1016/S0046-8177(98)90391-4
M3 - Article
C2 - 9445135
AN - SCOPUS:0031964567
SN - 0046-8177
VL - 29
SP - 60
EP - 64
JO - Human Pathology
JF - Human Pathology
IS - 1
ER -